Viewpoint Molecular Targeting

About:

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostics for personalized medicine.

Website: http://viewpointmt.com

Twitter/X: viewpoint_mt

Top Investors: National Cancer Institute, National Institutes of Health, Small Business Innovation Research

Description:

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Total Funding Amount:

$34.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Coralville, Iowa, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)viewpointmt.com

Founders:

Frances Johnson, Heyward Coleman, Michael Schultz

Number of Employees:

1-10

Last Funding Date:

2021-01-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai